Insider Selling: Indivior (NASDAQ:INDV) CFO Sells 36,000 Shares of Stock

Indivior PLC (NASDAQ:INDV) CFO Ryan Preblick sold 36,000 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $37.70, for a total value of $1,357,200.00. Following the sale, the chief financial officer owned 284,751 shares in the company, valued at $10,735,112.70. This trade represents a 11.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Indivior Trading Up 2.3%

Shares of Indivior stock opened at $38.26 on Wednesday. Indivior PLC has a twelve month low of $13.44 and a twelve month high of $41.00. The stock has a market capitalization of $4.66 billion, a P/E ratio of 19.62 and a beta of 0.88. The business’s fifty day moving average price is $34.94 and its 200 day moving average price is $34.19.

Indivior (NASDAQ:INDV) last issued its earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The firm had revenue of $317.00 million for the quarter. As a group, sell-side analysts predict that Indivior PLC will post 4.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Weiss Ratings lowered Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $39.33.

Hedge Funds Weigh In On Indivior

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP acquired a new position in shares of Indivior during the third quarter worth approximately $26,000. Raymond James Financial Inc. acquired a new position in shares of Indivior during the second quarter worth approximately $26,000. Salomon & Ludwin LLC acquired a new position in shares of Indivior during the fourth quarter worth approximately $30,000. Harbor Capital Advisors Inc. boosted its position in shares of Indivior by 309.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after buying an additional 781 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after buying an additional 460 shares during the period. 60.33% of the stock is currently owned by institutional investors and hedge funds.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.